According to a new market research study on “Europe Liver Cancer Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and End User” is expected to reach US$ 4,308.57 million by 2028 from US$ 2,567.59 million in 2021. The market is estimated to grow at a CAGR of 7.7% from 2021 to 2028.
The “Europe liver cancer diagnostics market” is segmented on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held a larger share of the market; and the imaging segment is expected to register a higher CAGR during the forecast period. Further based on laboratory tests, the Europe liver cancer diagnostics market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held the largest market share; and the same segment is expected to register the highest CAGR in the market during the forecast period. Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held a larger share of the market; and the same segment is expected to register a higher CAGR during the forecast period. Based on country, the Europe liver cancer diagnostics market is segmented into Germany, France, the UK, Italy, Spain, and Rest of Europe. In 2021, Germany held the largest market share; and the UK is expected to grow at the fastest CAGR during the forecast period.
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis – https://www.businessmarketinsights.com/sample/BMIRE00025041
Hepatocellular carcinoma is the most frequent type of liver cancer. It starts in the major type of liver cell (hepatocyte) and is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Other kinds of liver cancer are significantly less prevalent, such as intrahepatic cholangiocarcinoma and hepatoblastoma. Cancer that begins in another area of the body, such as the colon, lung, or breast, and then spreads to the liver is called metastatic cancer.
Major key players covered in this report:
- Abbott
- bioMerieux SA
- HOFFMANN-LA ROCHE LTD.
- Illumina, Inc.
- Koninklijke Philips N.V.
- QIAGEN
- Siemens Healthineers AG
- THERMO FISHER SCIENTIFIC INC.
- GE Healthcare
- Perspectum
Moreover, metastatic colon cancer is a kind of cancer that starts in the colon and spreads to the liver. For instance, In Europe, HCC accounts for around 47,000 deaths per year. The incidence is comparatively low except in Southern Europe, where the age-standardized incidence rate in men is 9.8 per 100,000 compared with 3.8 in Northern Europe, 4.6 in central and Eastern Europe, and 7.2 in Western Europe. However, in the UK, the HCC-based mortality rate is expected to rise by 14% between 2006 and 2025, representing the largest increase in male cancer.
Furthermore, being overweight or having obesity is a risk factor for liver cancer and non-alcoholic fatty liver disease is a common condition in obese people. People with a subtype of non-alcoholic fatty liver disease, known as non-alcoholic steatohepatitis (NASH), might develop cirrhosis, which can cause liver cancer. Certain inherited metabolic diseases can lead to cirrhosis. Lifestyle and behaviors, such as smoking cigarettes and drinking alcohol, are the leading cause of cirrhosis, which is linked with an increased risk of liver cancer.
Immediate delivery of our off-the-shelf reports and prebooking of upcoming studies, through flexible and convenient payment methods – https://www.businessmarketinsights.com/buy/single/BMIRE00025041
The research on the Europe Liver Cancer Diagnostics market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitor’s methodologies. The research also segments the Europe Liver Cancer Diagnostics market on the basis of end user, product type, application, and demography for the forecast period 2021–2028. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.
This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Europe Liver Cancer Diagnostics market.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact us:
If you have any questions about this report or would like further information, please contact us:
Contact person: Sameer Joshi
Email: sales@businessmarketinsights.com
Phone: +16467917070
